Citation Impact
Citing Papers
The Utility of Oral Glucose Tolerance Testing for Diagnosis and Assessment of Treatment Outcomes in 166 Patients with Acromegaly
2008
Place of Cabergoline in Acromegaly: A Meta-Analysis
2011
Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas
2009
Guidelines for Acromegaly Management: An Update
2009
Effective Combination Treatment with Cabergoline and Low-Dose Pegvisomant in Active Acromegaly: A Prospective Clinical Trial
2012
Glucose Tolerance and Somatostatin Analog Treatment in Acromegaly: A 12-Month Study
2009
Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel® therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension
2009
Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review
2010
LSD but not lisuride disrupts prepulse inhibition in rats by activating the 5-HT2A receptor
2009
A consensus on the diagnosis and treatment of acromegaly complications
2012
Acromegaly
2006 Standout
Repeat endoscopic transsphenoidal surgery for acromegaly: remission and complications
2013
Morbidity after Long-Term Remission for Acromegaly: Persisting Joint-Related Complaints Cause Reduced Quality of Life
2005
Pegvisomant and cabergoline combination therapy in acromegaly
2012
The Antitumoral Effects of Somatostatin Analog Therapy in Acromegaly
2005
Radiotherapy and radiosurgery in acromegaly
2008
Consensus statement: medical management of acromegaly
2005
Cancers Associated with Acromegaly
2006
Acromegaly and Pregnancy: A Retrospective Multicenter Study of 59 Pregnancies in 46 Women
2010
The association of Streptococcus bovis/gallolyticus with colorectal tumors: The nature and the underlying mechanisms of its etiological role
2011 Standout
Dopamine Resistance of Prolactinomas
2003
Insulin-Like Growth Factors I and II. Peptide, Messenger Ribonucleic Acid and Gene Structures, Serum, and Tissue Concentrations*
1989 Standout
Pharmacotherapy or Surgery as Primary Treatment for Acromegaly?
2000
Radiotherapy for Pituitary Adenomas
2008
Outcome of Gamma Knife Radiosurgery in 82 Patients with Acromegaly: Correlation with Initial Hypersecretion
2005
Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future
2016
European evidence based consensus for endoscopy in inflammatory bowel disease
2013 Standout
Clinical use of cabergoline as primary and adjunctive treatment for acromegaly
2008
Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours
2009
Risk of Thyroid Nodular Disease and Thyroid Cancer in Patients with Acromegaly – Meta-Analysis and Systematic Review
2014
Acromegaly: Re-thinking the cancer risk
2007
Risk of colorectal neoplasm in patients with acromegaly: A meta-analysis
2008
Acromegaly, growth hormone and cancer risk
2008
Cushing's syndrome
2015 Standout
Acromegaly pathogenesis and treatment
2009
Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002)
2010
Molecular defects in the pathogenesis of pituitary tumours
2003
Cabergoline Decreases Somatotroph Adenoma Size: A Case Report
2004
Medical consequences of acromegaly: What are the effects of biochemical control?
2007
Psychedelics
2016 Standout
Variation in GH and IGF‐I assays limits the applicability of international consensus criteria to local practice
2007
Diabetes in acromegaly, prevalence, risk factors, and evolution: data from the French Acromegaly Registry
2011
Predictors of Tumor Shrinkage after Primary Therapy with Somatostatin Analogs in Acromegaly: A Prospective Study in 99 Patients
2006
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
2011 Standout
Radiosurgery for pituitary adenomas
2004
Acromegaly
1990
A prospective, multicentre study to investigate the efficacy, safety and tolerability of octreotide LAR® (long‐acting repeatable octreotide) in the primary therapy of patients with acromegaly
2007
Comparison between Six-Year Therapy with Long-Acting Somatostatin Analogs and Successful Surgery in Acromegaly: Effects on Cardiovascular Risk Factors
2006
Prevalence of discordant GH and IGF-I levels in acromegalics at diagnosis, after surgical treatment and during treatment with octreotide LAR®
2008
Gamma knife radiosurgery for acromegaly – long‐term experience
2006
Long-Term Evaluation of Postoperative Acromegalic Patients in Remission with Previous and Newly Proposed Criteria
2005
Thyroid Volume and Serum Thyroglobulin Levels in Patients with Acromegaly: Correlation with Plasma Insulin-Like Growth Factor I Levels*
1988
Primary medical therapy for acromegaly
2003
Recent advances in the neuropsychopharmacology of serotonergic hallucinogens
2014
Therapeutic Efficacy of the Somatostatin Analog SMS 201-995 (Octreotide) in Acromegaly
1990
Raloxifene decreases serum IGF-I in male patients with active acromegaly
2004
Irritable bowel syndrome
2016 Standout
Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
2013 Standout
Insulin and insulin-like growth factor signalling in neoplasia
2008 Standout
MEDICAL TREATMENT OF PROLACTINOMAS
1999
Pregnancy in acromegaly: experience from two referral centers and systematic review of the literature
2011
Evaluation of Disease Status with Sensitive Measures of Growth Hormone Secretion in 60 Postoperative Patients with Acromegaly1
1998
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
1997
Cabergoline Therapy of Growth Hormone & Growth Hormone/Prolactin Secreting Pituitary Tumors
2004
Repeat Transsphenoidal Surgery for the Treatment of Remaining or Recurring Pituitary Tumors in Acromegaly
2010
Acromegaly
1994
Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline
2011 Standout
Ulcerative colitis
2012 Standout
Nelson’s Syndrome: Complete Remission with Cabergoline but Not with Bromocriptine or Cyproheptadine Treatment
2004
Prolactinoma
2003
Recurrence of Hyperprolactinemia after Withdrawal of Dopamine Agonists: Systematic Review and Meta-Analysis
2009
The Physiology, Signaling, and Pharmacology of Dopamine Receptors
2011 Standout
Epidermal Growth Factor Induces the Functional Expression of Dopamine Receptors in the GH3 Cell Line*
1991
Fertility and infertility: Definition and epidemiology
2018 Standout
Acromegaly: An Endocrine Society Clinical Practice Guideline
2014 Standout
Induction of laminitis by prolonged hyperinsulinaemia in clinically normal ponies
2007 Standout
Long-Acting Somatostatin Analog Therapy of Acromegaly: A Meta-Analysis
2005
Diagnosis and Complications of Cushing’s Syndrome: A Consensus Statement
2003 Standout
Meta-Analysis on the Effects of Octreotide on Tumor Mass in Acromegaly
2012
Pituitary pars intermedia dysfunction: equine Cushing's disease
2002
Colonic neoplasia in acromegaly: increased proliferation or deceased apoptosis?
2011
Repeated colonoscopic screening of patients with acromegaly: 15-year experience identifies those at risk of new colonic neoplasia and allows for effective screening guidelines
2010
Mucus-penetrating nanoparticles for drug and gene delivery to mucosal tissues
2008 Standout
Stereotactic Radiosurgery for Pituitary Adenomas: A Review of the Literature
2004
Hypopituitarism following radiotherapy
2008
Dopamine Receptor Expression and Function in Corticotroph Pituitary Tumors
2004
Outcome of Cabergoline Treatment in Men with Prolactinoma: Effects of a 24-Month Treatment on Prolactin Levels, Tumor Mass, Recovery of Pituitary Function, and Semen Analysis
2004
Effects of two different somatostatin analogs on glucose tolerance in acromegaly
2002
Growth-hormone and prolactin excess
1998
Effects of octreotide exposure during pregnancy in acromegaly
2009
Hyperprolactinemia and Prolactinomas
2008
Pasireotide (SOM230): Development, mechanism of action and potential applications
2007
Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide
2007
The octreotide test dose is not a reliable predictor of the subsequent response to somatostatin analogue therapy in patients with acromegaly
2006
GROWTH HORMONE NEUROREGULATION AND ITS ALTERATIONS IN DISEASE STATES
1988
Comparison of pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy
2009
Conventional Pituitary Irradiation Is Effective in Lowering Serum Growth Hormone and Insulin-Like Growth Factor-I in Patients with Acromegaly
2006
Pregnancy and acromegaly: a review
2011
Surveillance of Patients at Increased Risk of Colon Cancer: Inflammatory Bowel Disease and Other Conditions
2008
The long‐term efficacy of conventional radiotherapy in patients with GH‐secreting pituitary adenomas
2005
Cushing's syndrome
2006 Standout
Surgical Interventions and Medical Treatments in Treatment-Naïve Patients With Acromegaly: Systematic Review and Meta-Analysis
2014
Drug Insight: cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women
2006
Effect of Different Dopaminergic Agents in the Treatment of Acromegaly
1997
Ghrelin: Structure and Function
2005 Standout
Growth hormone and the heart
2001
Plasma Insulin-Like Growth Factor-I/Somatomedin-C in Acromegaly: Correlation With the Degree of Growth Hormone Hypersecretion*
1988
The rise and rise of drug delivery
2005
Pituitary Tumor Registry: A Novel Clinical Resource1
2000
Gamma knife stereotactic radiosurgery for acromegaly
2007
Radiosurgery of growth hormone–producing pituitary adenomas: factors associated with biochemical remission
2007
Pathophysiology of the Neuroregulation of Growth Hormone Secretion in Experimental Animals and the Human*
1998 Standout
Endocrine Therapy of Breast and Prostate Cancer
1989
A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly
2008
Growth Hormone Receptor Antagonists: Discovery, Development, and Use in Patients with Acromegaly
2002
Treatment of Acromegaly with Dopamine Agonists
1992
Supramolecular Hydrogelators and Hydrogels: From Soft Matter to Molecular Biomaterials
2015 Standout
The concepts of stress and stress system disorders. Overview of physical and behavioral homeostasis.
1992 Standout
Impact of Treating Acromegaly First with Surgery or Somatostatin Analogs on Cardiomyopathy
2008
Optimizing Control of Acromegaly: Integrating a Growth Hormone Receptor Antagonist into the Treatment Algorithm
2003
Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout Mice
1998 Standout
Clinical Manifestations of Acromegaly
1992
The effects of putative 5-hydroxytryptamine receptor active agents ond-amphetamine self-administration in controls and rats with 5,7-dihydroxytryptamine median forebrain bundle lesion
1984
Forty Month Follow-Up of Persistent and Difficultly Controlled Acromegalic Patients Treated with Depot Long Acting Somatostatin Analog Octreotide
2007
Systemic Complications of Acromegaly: Epidemiology, Pathogenesis, and Management
2004 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
On the Mode of the Prolactin Release-Inhibiting Action of the Serotonin Receptor Blockers Metergoline, Methysergide, and Cyproheptadine*
1981
A Consensus on Criteria for Cure of Acromegaly
2010
Cabergoline in the Treatment of Acromegaly: A Study in 64 Patients
1998
Approach to the Patient with Persistent Acromegaly after Pituitary Surgery
2010
Rapid Regression of Pituitary Prolactinomas during Bromocriptine Treatment*
1980
Stereotactic Radiosurgery for Acromegaly
2014
Inhibitory effect of octreotide on growth hormone-induced IGF-I generation and organ growth in hypophysectomized rats
1991
Advances in the Treatment of Prolactinomas
2006
Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment
1997
Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide
2000
Prolactin-Lowering and -Releasing Drugs Mechanisms of Action and Therapeutic Applications
1983
Hyperprolactinemia in Men: Clinical and Biochemical Features and Response to Treatment
2003
Growth Hormone Secretion: Molecular and Cellular Mechanisms and In Vivo Approaches
2004
Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement
2013 Standout
Prolactin: Structure, Function, and Regulation of Secretion
2000 Standout
Growth of an aggressive tumor during pregnancy in an acromegalic patient
2012
Growth Factors and Cancer
1991 StandoutScience
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
2017 Standout
Resistance to Cabergoline as Compared with Bromocriptine in Hyperprolactinemia: Prevalence, Clinical Definition, and Therapeutic Strategy
2001
Effect of presurgical long-acting octreotide treatment in acromegaly patients with invasive pituitary macroadenomas: a prospective randomized study
2010
Treatment of Pituitary Gigantism with the Growth Hormone Receptor Antagonist Pegvisomant
2008
Acromegaly: historical perspectives and current therapy
2001
Demonstration of Enhanced Potency of a Chimeric Somatostatin-Dopamine Molecule, BIM-23A387, in Suppressing Growth Hormone and Prolactin Secretion from Human Pituitary Somatotroph Adenoma Cells
2002
Pasireotide Versus Octreotide in Acromegaly: A Head-to-Head Superiority Study
2014
Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates
2006
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
2016 Standout
A Critical Analysis of Pituitary Tumor Shrinkage during Primary Medical Therapy in Acromegaly
2005
Long-Term Treatment of Prolactin-Secreting Macroadenomas with Pergolide
2000
Guidelines for Perioperative Care in Elective Rectal/Pelvic Surgery: Enhanced Recovery After Surgery (ERAS®) Society Recommendations
2012 Standout
Treatment of Acromegaly with Pegvisomant during Pregnancy: Maternal and Fetal Effects
2007
Somatostatin and Somatostatin Analogue (SMS 201-995) in Treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut
1989
Reversible Hypopituitarism in Patients with Large Nonfunctioning Pituitary Adenomas*
1986
Dopamine Receptors: From Structure to Function
1998 Standout
Cocaine Receptors on Dopamine Transporters Are Related to Self-Administration of Cocaine
1987 StandoutScience
Nerve growth factor suppresses the transforming phenotype of human prolactinomas.
1993
American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly-2011 Update
2011
Responses of Markers of Bone and Collagen Turnover to Exercise, Growth Hormone (GH) Administration, and GH Withdrawal in Trained Adult Males1
2000
Hyperprolactinemia: Evaluation and Management
1992
Clinical Practice Guidelines for Multiple Endocrine Neoplasia Type 1 (MEN1)
2012
The American Association of Endocrine Surgeons Guidelines for Definitive Management of Primary Hyperparathyroidism
2016 Standout
Works of Renato Cozzi being referenced
Partial Surgical Removal of Growth Hormone-Secreting Pituitary Tumors Enhances the Response to Somatostatin Analogs in Acromegaly
2006
Pregnancy in acromegaly: a one-center experience
2006
GH/IGF-I normalization and tumor shrinkage during longterm treatment of acromegaly by lanreotide
2001
Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogue-naive patients with acromegaly
2009
Inhibitory effects of galanin on growth hormone (GH) release in cultured GH-secreting adenoma cells: Comparative study with octreotide, GH-releasing hormone, and thyrotropin-releasing hormone
1997
Effects of Lanreotide Autogel on Growth Hormone,Insulinlike Growth Factor 1, and Tumor Size in Acromegaly: a 1-Year Prospective Multicenter Study
2008
Lanreotide 60 mg, a Longer-Acting Somatostatin Analog: Tumor Shrinkage and Hormonal Normalization in Acromegaly
2000
Cabergoline in acromegaly: a renewed role for dopamine agonist treatment?
1998
First-line therapy of acromegaly: A statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group
2006
From macroprolactinoma to concomitant ACTH-PRL hypersecretion with Cushing’s disease
2000
Primary Treatment of Acromegaly with Octreotide LAR: A Long-Term (Up to Nine Years) Prospective Study of Its Efficacy in the Control of Disease Activity and Tumor Shrinkage
2006
High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial
2009
Differential Inhibition of Growth Hormone Secretion by Analogs Selective for Somatostatin Receptor Subtypes 2 and 5 in Human Growth-Hormone-Secreting Adenoma Cells in vitro
2001
Failure of radiotherapy in acromegaly
2001
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status
2004
Efficacy and tolerability of gamma knife radiosurgery in acromegaly: a 10‐year follow‐up study
2009
Neurosurgery restores late GH rise after glucose-induced suppression in cured acromegalics
1999
Four-Year Treatment with Octreotide-Long-Acting Repeatable in 110 Acromegalic Patients: Predictive Value of Short-Term Results?
2003
Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases
2001
Raloxifene lowers IGF-I levels in acromegalic women
2003
Octreotide for acromegaly
2007
Effects of high-dose octreotide LAR on glucose metabolism in patients with acromegaly inadequately controlled by conventional somatostatin analog therapy
2011
Effects of tamoxifen on GH and IGF-I levels in acromegaly
1997
Pegvisomant in acromegaly: Why, when, how
2007
CV 205-502 in acromegaly
1993
Estroprogestinic pill normalizes IGF-I levels in acromegalic women
2003
Somatostatin analogs and gallstones: A retrospective survey on a large series of acromegalic patients
2008
A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly
1999
Colonoscopic Screening and Follow-Up in Patients with Acromegaly: A Multicenter Study in Italy
2005
Treatment of acromegaly with SS analogues: Should GH and IGF-I target levels be lowered to assert a tight control of the disease?
2004
Chronic Treatment of Pathological Hyperprolactinemia and Acromegaly with the New Ergot Derivative Terguride*
1986
SIZE REDUCTION OF A PROLACTIN SECRETING ADENOMA DURING LONG‐TERM TREATMENT WITH THE DOPAMINE AGONIST LISURIDE
1980
Gamma-Knife Radiosurgery in Acromegaly: A 4-Year Follow-Up Study
2003
Relationship between Somatomedin-C and Growtyh Hormone Levels in Acromegaly: Basal and Dynamic Evaluation*
1986
Serum Type III Procollagen Propeptide Levels in Acromegalic Patients*
1986
Low Doses of Dopamine Agonists in the Long-Term Treatment of Macroprolactinomas
1985
Lanreotide 60 mg, a New Long-Acting Formulation: Effectiveness in the Chronic Treatment of Acromegaly
2003
EVIDENCE FOR A DOPAMINERGIC ACTIVITY OF METHYSERGIDE IN HUMANS
1977
Size Reduction of Macroprolactinomas by Bromocriptine or Lisuride Treatment*
1981
Medical Treatment of Acromegaly with SMS 201-995, a Somatostatin Analog: A Comparison with Bromocriptine*
1987
Effectiveness.of the dopamine agonist lisuride in the treatment of acromegaly and pathological hyperprolactinemic states
1980
Bromocriptine Does Not Alter Growth Hormone (GH) Responsiveness to GH-Rreleasing Hormone in Accromegaly*
1986